Utility of plasma GFAP as a biomarker for Alzheimer's Disease using chemiluminescent microparticle immunoassay
Eduard Bargay Pizarro, Daniel Morell García, Ana García Martin, Susana Tarongi Sanchez, Lara Nuñez Santos, Lorena Garcia Medina, María Santés Bertó, Guillermo Amer Ferrer · 2025
Read Utility of plasma GFAP as a biomarker for Alzheimer's Disease using chemiluminescent microparticle immunoassay by Eduard Bargay Pizarro, Daniel Morell García, Ana García Martin, Susana Tarongi Sanchez, Lara Nuñez Santos, Lorena Garcia Medina, María Santés Bertó, Guillermo Amer Ferrer (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716475.txt.
Description
Eduard Bargay Pizarro and co-authors validate a plasma GFAP test for Alzheimer disease on a common low-cost platform. GFAP in blood is a promising marker of the disease. Most studies use pricey single-molecule platforms to measure it.
Their clinic cohort held patients with mild impairment or dementia. Brain scans, thinking tests, and spinal fluid markers were gathered. Blood GFAP was measured by a standard chemiluminescent assay. The platform is widespread in hospital labs worldwide. Many patients were classed as Alzheimer type by fluid markers. The blood test's value was checked against that standard. A cheap, routine assay could widen access to screening. The study supports that wider use case.
Catalog record
| CREATOR | Eduard Bargay Pizarro, Daniel Morell García, Ana García Martin, Susana Tarongi Sanchez, Lara Nuñez Santos, Lorena Garcia Medina, María Santés Bertó, Guillermo Amer Ferrer |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |